Skip to content
value.today

OptiNose, Inc.

OPTNUnlisted company
$135 Mlast known market cap, Jan 2024 — no current value
Compare
World rank
—
no current market cap
Revenue
$49 M
Dec-2020 ending year
value.today research
Net income
$-100 M
-203.1% margin
value.today research
Employees
—

OptiNose, Inc. in brief

OptiNose, Inc. is an unlisted company in the Pharmaceutical industry, based in Pennsylvania, USA. It was founded in 2010. In the year to Dec 2020 it had sales of $49 M and a net loss of $100 M.

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

OptiNose, Inc. timeline

2 events, 2010–2017
  1. 2010
  2. 🏁
    · approximate
    Founded
  3. 2017
  4. 🔔
    · approximate
    Initial public offering on Nasdaq

Events of OptiNose, Inc. from the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

More about OptiNose, Inc.

Acquisitions and changes
No longer listed: ticker OPTN is not in the SEC's, the US exchanges' or FINRA's lists of traded securities (checked 14 November 2026).

Market cap history

$0 M$108 M$215 M$323 M$431 M20202021202220232024

World rank over time

▼ down 7,730 places since 2020
2020-01-01: #12207#12,20720202021-01-01: #15173#15,17320212022-01-07: #20620#20,62020222022-12-25: #18360#18,36020222023-07-30: #20246#20,24620232024-01-05: #19937#19,9372024

Rank in USA: #2,652 (Jan 2020) · #3,180 (Jan 2021) · #4,121 (Jan 2022) · #3,739 (Dec 2022) · #3,960 (Jul 2023) · #3,502 (Jan 2024)

Annual results

Revenue
$49 M
Operating income
—
Net income
$-100 M

Dec-2020 ending year

Markets and events: OptiNose, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2025-05-15
130,621
8.39 days to cover
Shares sold short, last 13 reportsAll stocks →

Trading halts

  • 2025-05-20 23:50 UTC, code D, resumed 04:00 UTC
  • 2025-03-04 14:30 UTC, code LUDP, resumed 14:35 UTC
  • 2024-12-31 15:19 UTC, code LUDP, resumed 15:24 UTC
  • 2024-12-31 00:50 UTC, code T3, resumed 14:00 UTC

Fails to deliver

  • : 59 shares at $9.10
  • : 1,354 shares at $9.00
  • : 909 shares at $9.15
  • : 5 shares at $9.15
  • : 807 shares at $9.14

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

How OptiNose, Inc. compares in Pharmaceutical

  • Revenue$49 M · higher than 15% of 324
  • Net margin-203.1% · higher than 2% of 313

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
OptiNose, Inc.🇺🇸$135 M—-203.1%—
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Jan 5, 2024 (last known)
Annual results:
Dec-2020 ending year
Balance sheet:
Dec-2020 ending year
Profile updated:
Nov 14, 2026

Figures from value.today research.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at OptiNose, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show OptiNose, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about OptiNose, Inc.? Suggest a correction